Using tritiated arginine-8-vasopressin I3HIAVP, vasopressinspecific binding sites were detected on human platelet membranes. One class of high-affinity binding sites was characterized with an equilibrium dissociation constant of 1.01±0.06 nM and a maximal binding capacity of 100±10 fmol/mg of protein (n = 12). Highly significant correlations were found between the relative agonistic (r = 0.87, P = 0.002) or antagonistic (r = 0.99, P = 0.007) vasopressor activities of a series of 13 AVP structural analogues and their relative abilities to inhibit 13HIAVP binding to platelet receptors whereas no such relationship existed when antidiuretic activities were considered (r = 0.28, P = 0.47). AVP did not stimulate cyclic AMP production of human platelets; on the contrary, high AVP concentrations (10-6 M) inhibited cyclic AMP production measured in basal and prostaglandin El-stim- The observation that human platelets bear AVP receptors belonging to the vascular class suggests that platelet receptors can be used to further explore the role of vasopressin in cardiovascular homeostasis.
Introduction
The understanding of the role of vasopressin (AVP)' in blood pressure regulation (1) has been aided by the development of new tools such as sensitive radioimmunoassays and, more recently, specific and potent AVP antagonists acting selectively on either the renal or vascular AVP receptors (2) (3) (4) . It is now well established that endogenous AVP does play a role in the maintenance of blood pressure in several experimental conditions in animals including dehydration, hemorrhage, adrenal insufficiency, or hypertension induced by desoxycorticosterone (see Reference 1 for review). In humans, the cardiovascular role of AVP is less well documented, except for the observation that high plasma and urinary AVP levels are encountered in severe forms of human hypertension (5) .
Vasopressin receptors can be classified into two main types on the basis of structure activity and radioligand binding studies with AVP analogues. The first class of receptors, termed VI, appears to mediate vasoconstriction, glycogenolysis, and platelet aggregation and acts by stimulating phosphoinositide breakdown and mobilizing calcium. The second class of receptors, termed V2, activates adenylate cyclase and is responsible for the antidiuretic action of AVP. In animal preparations, smooth muscle cells, or liver extracts are used for investigating AVP specific receptors of the vascular type (6, 7), whereas kidney preparations are used to study AVP renal type receptors (8) . These tissues are rarely available from man. For this reason, Block et al. (9) used human mononuclear phagocytes to characterize specific AVP receptors which are presumably of the renal type. Because Haslam and Rosson (10) showed that vasopressin aggregates human platelets in the presence ofcalcium and thus suggested "a parallel between platelet aggregation and the contraction of smooth muscle," we attempted to demonstrate that AVP would bind specifically to these human cells and to identify the type of receptor involved. In fact, human platelet membranes possess specific binding sites for [3H] arginine-8-AVP ([3H]AVP). The pharmacologic characteristics of these binding sites are consistent with those of the VI vascular type of AVP receptor. Accordingly, platelets may become a useful tool for exploring further the cardiovascular effects of AVP in humans.
Methods
Pharmacological agents. The radioligand [3H] AVP was purchased from New England Nuclear (Boston, MA). Its riliochemical purity was checked by high pressure liquid chromatography with a reverse-phase C18 column from Waters Associates (Milford, MA) using a gradient from 23% to 29% acetonitrile and 0.01 M ammonium acetate, pH 6.7.
The specific activity of [3HJAVP was close to 55 Ci/mmol. Bovine serum albumin, AVP, creatine phosphate, creatine phbsphokinase, EGTA, ,Bmercaptoethanol, ATP, cyclic AMP, GTP, epinephrine, 5'-guanylylimidodiphosphate (GppNHp), forskolin, and prostaglandin El (PGEI) were obtained from Sigma Chemical Co. (St. Louis, MO). The AVP analogues listed in Table I were generous gifts of Dr. Hofbauer (Ciba-Geigy, Switzerland), Dr. Mulder (Ferring AB, Malmo, Sweden), and Dr. Manning (Toledo, OH) or were purchased from Peninsula Laboratory (San Carlos, CA).
Platelet particulate preparation. Individual 50-ml units of platelet concentrates were purchased from the local blood bank. These units were prepared from 450 ml of human blood collected into polypropylene bags containing 63 ml of a citrate-phosphate-dextrose-adenine solution (each 63 ml contains 2 g of glucose, 1.66 g of sodium citrate anhydrous, gto sediment platelets. The platelet pellet was suspended in 1.5 ml buffer (TrisHC1 50 mM + EDTA 5 mM, pH 7.4) then frozen in liquid nitrogen. The preparation was allowed to thaw at room temperature and transferred to high-speed centrifuge tubes. High-speed centrifugation (30,000 g for 15 min at 40C) was repeated three times after rinsing the pellet with 5 ml of cold buffer. The washed pellet was resuspended in 2.5 ml of buffer and stored frozen at -700C. All the previous steps were carried out with plastic material, and repeated saturation analysis showed that the receptor was stable under these conditions for a period of up to 3 mo. Intact platelets were also ptepared for binding experiments. The platelet-rich plasma pellet (instead of being frozen for particulate preparation) was resuspended in buffer (Tris-HCI 50 mM, pH 7.4, NaCl 138 mM, EDTA 5 mM) and then centrifuged twice at 16,000 g for 15 min at 250C. The washed intact platelets (1 X i16/Ml) were resuspended in assay buffer and used the same day for binding experiments.
Hormone binding assays. For the binding assays, platelet particulate aliquots were thawed and diluted (0.8 to 1 mg/ml final concentration determined with Bradford's method (11) in the assay buffer containing 50 mM Tris-HCI and 4 mM MgC12, pH 7.4. Duplicate samples were incubated at 30°C in 5 ml polypropylene plastic tubes (Sarstedt, West Germany) in a final volume of 230 Ml containing I mg/ml bovine serum albumin and different concentrations of [3H] AVP ranging from 0.3 to 15 mM.
For saturation and competition analysis, the incubation time was 30 min. For competition experiments with the structural analogues ofAVP, 13 concentrations of these compounds were added to the reaction mixtdire containing 1-2 nM [3H]AVP. Incubation was terminated by adding 5 ml of ice-cold assay buffer and free separated from bound [3H] AVP by rapid (I ml/s) filtration over Whatman GF/C glass fiber filters (Whatman Chemical Separation, Clifton, NJ) previously soaked in assay buffer plus albumin I mg/ml for 1 h. The filters were rinsed four times with 5 ml ofbuffer and transferred to vials containing 4 ml of Hydrofluor (National Diagnostics, Inc., Somerville, NJ) as scintillation fluid and the radioactivity was determined in a Packard Tricarb scintillation counter (Packard Instrument Co., Inc., Downers Grove, ILL) at an efficiency of 52%. The stability ofthe tracer in the incubation medium was checked before and at the end of the incubation period by high pressure liquid chromatography and thin-layer chromatography. In saturation experiments, unspecific binding of [3H] AVP was defined as radioactivity bound to platelet particulates which was not competed by 100 nM of unlabeled AVP. Specific binding was, therefore, defined as total binding minus unspecific binding.
Adenylate cyclase activity assay. Statistical evaluation. Values given in the text, figures, and tables are mean±SEM of n experiments. Data from saturation and competition analysis were analyzed using an iterative nonlinear least squares curvefitting program. The program and the mathematical models upon which the program is based are described elsewhere (13) . For saturation experiments, data analysis was done using-the following equation: For platelet aggregation experiments, the effect of AVP was analyzed using the following equation:
where E = degree of platelet aggregation induced by AVP for a given concentration, E.. = maximum effect induced by AVP, L = corresponding AVP concentration, and EC50 = concentration ofAVP inducing 50% of maximum aggregation.
In the presence of a vasopressin-competitive antagonist, the following equation was used: Effect ofA VP on adenylate cyclase activity. The production of cyclic AMP in basal conditions was 28±3 pmol/mg of protein* min and was not altered by the addition of GTP (10-' M) (26±3 pmol/mg ofprotein * min). Sodium chloride, by itself, did not significantly alter the basal production of cyclic AMP. AVP did not further stimulate cyclic AMP production with the same conditions (Fig. 7 A) . On the contrary, AVP reduced basal cyclase activity by, respectively, 2% for 10-15 M AVP, 12% for 10-10 M AVP, and 22% for 10-6 M AVP. No further inhibition was observed for greater AVP concentrations (i.e., 10-5 and 10-4 M). The specific vascular antagonist, d(CH2)5Tyr(Me)AVP( 10-8 M), completely reversed the inhibitory effect of AVP, whereas 100 times larger doses (10-6 M) of the renal antagonist, d(CH2)5DIleu2Ala4AVP were required to obtain the same result. Both antagonists alone had no influence by themselves on cyclic AMP levels. By comparison, 10-4 M epinephrine reduced basal adenylate cyclase activity by 30% (n = 11 for the entire series of experiments). Table II . pK, = -log Ki, Ki = binding dissociation constant at equilibrium for the corresponding analogue, (M). For vasopressor activities references, see Table II . 10-6 M PGE, increased cyclic AMP production to 465±90 pmol/mg of protein * min (Fig. 7 B) . Only the greatest concentration of AVP ( 10-6 M) was able to reverse partially the stimulatory effect ofPGEI (-17%) to the same extent as epinephrine 10-4 M (-15%), (n = 8 for the entire series of experiments).
In the presence of forskolin 10-4 M, cyclic AMP production increased to 719 pmol/mg of protein * min (Fig. 7 C) . The addition of AVP did not significantly modify forskolin action whereas epinephrine 10-4 M partially blocked it (-9%).
Effect ofA VP on platelet aggregation with or without specific antagonists. AVP induced aggregation of platelets in heparinized platelet-rich plasma in a dose-dependent fashion with EC50 = 28±2 nM (n = 8 exp.). Neither the vascular antagonist d(CH2)5Tyr(Me)AVP nor the renal antagonist d(CH2)5DIleu-AlaAVP had any effect on platelet aggregation when used alone (data not shown). The vascular antagonist (Figs. 8 and 10 ) potently blocked the aggregating action of AVP with a pA2 value of 8.10±0.23 (n = 4), whereas much greater concentrations of the renal antagonist ( Fig. 9 and 10) were required in order to exert the same effect (pA2 = 6.67±0.12, n = 4). The Iso values for the vascular and renal antagonists in these experiments were respectively 8±2 and 232±4 nM, in the same order of magnitude of their corresponding Ki values derived from the competition experiments of AVP binding to platelet particulates.
Discussion
This study shows that blood platelets may prove a convenient biological tool for exploration of AVP receptors in man. It also further supports the observations of Haslam and Rosson (10) that human platelet AVP receptors belong to the V 1 or vascular class. [3H] AVP specifically binds to a low-capacity, high-affinity single class of sites on human platelet particulates. [3H] AVPspecific binding is saturable with time, it is dependent on the concentration of both the ligand and protein preparation, and it is reversible. The k-off values generated from our dissociation experiments with either cold AVP in excess (0.036 min-') or with infinite dilution (0.039 min-') fall within the range reported for other vasopressin receptor preparations (from 0.035 min-' for pig renal medullary membrane receptors to 0.13 min-' for pig LLC-PKI cells, cf. Table II ofReference 21 ). The same applies constant value obtained from the kinetic experiments was 0.83 nM, and that value derived from the competition experiments with unlabeled AVP was 1.22 nM. These values are consistent and are in agreement with the dissociation constant values reported in the literature for AVP-specific receptors, which range from 0.4 to 38 nM, varying with the type of preparation and the species investigated (6-9, 15-21). The same applies to the maximum binding capacity of our preparation (100 fmol/mg), which is within the range reported in the literature for AVP receptor concentrations in different tissues (21) . It is worth noting that the binding parameters estimates that we found were identical, whether we used total binding data or so-called specific binding data in the presence of an excess ofunlabeled hormone. It indicates that our mathematical model, as would be predicted, adequately fitted the binding parameters Kd and B., therefore, making it unnecessary to include experimental data points with unlabeled hormone. The traditional approach of using excess unlabeled hormone can introduce error. In addition, one may consider this alternative and practical method when characterizing a new receptor without previous information about the affinity ratio between the high-affinity binding site and nonsatu- to our k-on value, 4.3 X I07 M' X min-', falling within the 1.1 to 6.7 X I07 M-' X min' range reported by others (see Reference 21) . The analysis ofbinding at equilibrium revealed an apparent equilibrium dissociation constant at 1.01 nM. The dissociation Previous studies have shown that AVP receptors from several species discriminate among neurohypophyseal peptides and closely related synthetic structural analogues (6) (7) (8) (15) (16) (17) (18) . For the series of agonists we tested in competition experiments, we found a highly significant correlation between their relative affinities for binding to the preparations and their relative vasopressor potencies in vivo, whereas no correlation between binding affinities and antidiuretic potencies was disclosed. Such specificity for the hormonal binding-effect relationship suggests In competition and saturation experiments, no significant effect of a synthetic analogue of GTP, GppNHp, on the affinity and capacity of the human platelet AVP receptor was detected.
Such lack of effect of this nucleotide was also found for the hepatocyte receptor and the mesenteric arteries receptor (other V1-vascular type receptors), whereas it is fully effective at the V2-renal receptor level (22) . The absence of effect of GppNHp on the affinity of the platelet vasopressin receptor suggests that this receptor is not directly coupled to the adenylate cyclase system.
The effect of AVP on cyclic AMP production is a valuable tool for differentiating renal type receptors (stimulating cyclic AMP production) from vascular-type receptors (acting through calcium mobilization). In this study, the absence of increased cyclic AMP production in the presence of physiologic amounts of AVP and even the reduction of cyclic AMP production for a higher vasopressin concentration (known to cause a maximum increase in cAMP production by renal receptors [21, 22] ) argue against a renal type of receptor on human platelets. This inhibitory effect of AVP on platelet particulate production of cyclic AMP recently has been reported by Vanderwel et al. (23) . These authors also found that AVP concentration causing half-maximal inhibition of adenylate cyclase activity was 1.2±0.4 nM, in agreement with our results. The reduction ofcAMP production by 10-6 M AVP was also observed in the presence of a stimulus like PGEI. No increase of cAMP production by vasopressin in a preparation stimulated by forskolin is clearly distinct from the synergism of vasopressin and forskolin recently reported for renal medullary tubules (24) .
However, previous observations using intact platelets (25) or cultured aortic smooth muscle cells (also bearing VI AVP receptors [6] showed that AVP had no detectable effect on cyclic AMP production in these intact cells. Despite the fact that, in both intact and broken cell preparations, AVP did not stimulate cyclic AMP production (therefore, ruling out a renal type receptor), one might wonder why no cyclic AMP inhibition is encountered with intact cells whereas cyclic AMP inhibition is reported with broken cell preparations. This suggests that unidentified factors may exist that modulate the effector system with which the AVP-V 1 receptor complex interacts. In addition, further investigations are needed to find out whether the effect of AVP on cyclic AMP production is directly linked to the adenylate cyclase system, or whether it is secondary to the activation of cyclic GMP-dependent protein kinase G and calcium dependent protein kinase C (26). Recently, Keppens and De Wulf (27) showed that vasopressin and angiotensin enhanced the activity ofliver phosphodiesterase, accounting for their cyclic AMP lowering effect. Such an effect might also explain the effect of AVP on platelet cyclic AMP levels.
We confirm that AVP causes platelet aggregation with an EC50 value (28 nM) 
